BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35751140)

  • 21. Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research.
    Samy A; Ozdemir MK; Alhajj R
    Sci Rep; 2023 Feb; 13(1):2704. PubMed ID: 36792691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
    Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
    Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SF3B1 mutant myelodysplastic syndrome: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-mutation of
    Song J; Moscinski L; Yang E; Shao H; Hussaini M; Zhang H
    In Vivo; 2023; 37(3):985-993. PubMed ID: 37103105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic
    Foy A; McMullin MF
    J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
    Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
    Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].
    He F; Li T; Li YF; Tang P; Sang LN; Huang YM; Sun L; Liu L
    Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):681-687. PubMed ID: 37263951
    [No Abstract]   [Full Text] [Related]  

  • 34. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
    Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process.
    Jiang M; Chen M; Liu Q; Jin Z; Yang X; Zhang W
    Front Oncol; 2023; 13():1116438. PubMed ID: 37007111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
    Duetz C; Westers TM; In 't Hout FEM; Cremers EMP; Alhan C; Venniker-Punt B; Visser-Wisselaar HA; Chitu DA; de Graaf AO; Smit L; Jansen JH; van de Loosdrecht AA
    Br J Haematol; 2021 May; 193(4):798-803. PubMed ID: 33765355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
    Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
    Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
    Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.